Clinical Trials Browser

Interventional × Mesothelioma, Malignant × atezolizumab × Clear all

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT03228537 2025-11-10

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Phase 1 Active not recruiting

28 enrolled 17 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04996017 2025-03-13

AtezoMeso

Phase 3 Recruiting

162 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT04480372 2024-07-01

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Phase 2 Completed

68 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT05765084 2024-05-16

Immuno-MESODEC

Phase 1/2 Recruiting

15 enrolled

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Wilms Tumor

NCT03654833 2023-03-14

MiST

Phase 2 Unknown

186 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03786419 2021-05-13

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Phase 2 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant, Thoracic Neoplasms

Clinical Trials

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

AtezoMeso

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Immuno-MESODEC

MiST

Immunological Variables Associated to ICI Toxicity in Cancer Patients

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma